FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Obesity is a recently defined illness whose diagnosis and treatment continue to be stigmatized. Currently, due to lifestyle changes brought on by technological advancements and the wide availability and affordability of high-calorie foods, millions of people around the world suffer from obesity and/or its sequelae. Finding adequate prevention and treatment options would therefore lead to massive improvements in the duration and quality of life of affected individuals. In this review, we searched the PubMed database for studies exploring the safety and efficacy of the five medications currently approved by the FDA for the treatment of obesity. We included only studies pertaining to adult patients that have been published between 2012 and 2022. We found evidence that all the drugs analyzed such as orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, and semaglutide appear to be effective in inducing weight loss, with the suggestion that semaglutide may have superior efficacy. However, a massive obstacle in developing treatment guidelines remains the lack of prolonged studies monitoring the long-term safety and efficacy of obesity medications. Nevertheless, in patients at risk of complications from obesity, the benefits of losing fat mass may outweigh the potential side effects associated with these medications and clinicians should prescribe whichever of the FDA-approved pharmacotherapy they deem most appropriate for the patient's specific set of circumstances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Q., Wang, Y., Hao, Q., Vandvik, P. O., Guyatt, G., Li, J., Chen, Z., Xu, S., Shen, Y., Ge, L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)01640-8 · Cited by 279
RetractedWadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114 · cited 3×
“, 2021 [31] 611 Semaglutide plus intensive behavioral therapy vs placebo plus intensive behavioral therapy 68 weeks Mean body weight change from baseline was -16.”
BackgroundInfluentialRubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995 · cited 1×
“, 2022 [28] 338 Semaglutide group or liraglutide group or placebo group plus diet and physical activity 68”
BackgroundKhera, R., Murad, M. H., Chandar, A. K., Dulai, P. S., Wang, Z., Prokop, L. J., Loomba, R., Camilleri, M., & Singh, S. (2016) · JAMA · doi:10.1001/jama.2016.7602 · Cited by 865
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288 · cited 1×
“4 mg once weekly for the degree of weight loss, efficacy, and tolerability [32].”
BackgroundLiraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0343-6 · Cited by 217 · cited 1×
“Liraglutide is especially beneficial in overweight or obese diabetic patients as it has also been established as an effective therapy for better glycemic control in type 2 diabetics as an adjunct to oral anti-diabetic medications and/or insulin [30].”
BackgroundGorgojo‐Martínez, J. J., Basagoiti‐Carreño, B., Sanz‐Velasco, A., Serrano‐Moreno, C., & Almodóvar‐Ruiz, F. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13399 · Cited by 82 · cited 3×
“7 kg with liraglutide), fasting glucose level, systolic blood pressure, LDL cholesterol, and alanine transaminase [16].”
BackgroundInfluentialGrabarczyk, T. R. (2018) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2048 · Cited by 37
Cited by
Petrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060288 · Cited by 41
Anam, M., Maharjan, S., Amjad, Z., Abaza, A., Vasavada, A. M., Sadhu, A., Valencia, C., Fatima, H., & Nwankwo, I. (2022) · Cureus · doi:10.7759/cureus.32610 · Cited by 35
“Currently, Food and Drug Administration (FDA) has approved five drugs for long-term use for obesity which includes orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and semaglutide of which phentermine is the commonly prescribed option [11].”
BackgroundDellgren, J. L., Persad, G., & Emanuel, E. J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01356-4 · Cited by 33
The effect of obesity pharmacotherapy on body composition, including muscle mass
Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01533-3 · Cited by 28
“Semaglutide, another GLP-1 receptor agonist, is an antidiabetic and anti-obesity medication used for the treatment of T2DM as well as for long-term weight management [24].”
Leonhard, A. G., Josey, K., Castaneda, J. M., Chee, M., Duan, K. I., Nadeem, H., Plumley, R., Triplette, M., Smith, N. L., Au, D. H., et al. (2026) · Annals of the American Thoracic Society · doi:10.1093/annalsats/aaoag047 · Cited by 3
Metadata
- Authors
- Idrees, Z., Cancarevic, I., & Huang, L.
- Venue
- Cureus
- Published
- 2022-09-17
- Volume
- 14
- Issue
- 9
- Pages
- e29262-e29262
- ISSN
- 2168-8184 (ISSN-L)
- OpenAlex
- W4296187800
- Cited by
- 63
- References
- 10
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade. https://app.cochat.ai/papers/10.7759/cureus.29262
- The paper
- Idrees, Z., Cancarevic, I., & Huang, L. (2022). FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade. Cureus. https://doi.org/10.7759/cureus.29262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.